Document Detail


A study of drug utilisation and cost of treatment in patients hospitalised with unstable angina.
MedLine Citation:
PMID:  11214788     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The current study was designed to investigate drug utilisation in the management of unstable angina in India and to calculate the costs incurred by patients in the treatment of a single episode of unstable angina. METHODS: We conducted a prescription survey to examine the use of antianginal drugs in patients with unstable angina in a tertiary care Indian hospital. The use of concurrent medications such as antidiabetic, antihypertensive and lipid-lowering agents was also examined. Data on the cost of treatment, investigations, income, and family size were collected from the case histories or direct interviews with the patients/relatives. RESULTS: A total of 336 consecutive prescriptions were evaluated. Aspirin was the most frequently prescribed drug (98%) followed by nitroglycerin infusion (90%) and enoxaparin (52%). One of the heparins was used by 89% of all patients and beta-blockers by up to 62% of the patients. Besides antianginals, antihypertensive (49%) and antidiabetic (16%) drugs were commonly coadministered. The mean (+/- SD) cost of treatment of a single episode of unstable angina in the hospital was US $494 (+/- 271) against an annual per capita income of US $245. The mean (+/- SD) cost incurred by the patients due to drugs alone during the hospital stay was US $70 (+/- 18) and enoxaparin accounted for 60% of the expenditure due to drugs. CONCLUSIONS: The results of our study show that low-molecular-weight heparin, enoxaparin, is replacing unfractionated heparin in the treatment of unstable angina. In view of the use of costly new drugs, there is an urgent need for carrying out pharmacoeconomic analysis in developing countries as the treatment of a single episode of unstable angina imparts a considerable economic burden on the patient.
Authors:
S Malhotra; A Grover; N K Verma; V K Bhargava
Related Documents :
15526788 - Effects of previous grazing nutrition and management on feedlot performance of cattle.
7361768 - Chronopharmacology: a therapeutic frontier.
9061268 - Treatment of benign prostatic hyperplasia. a pharmacoeconomic perspective.
19895188 - Cost-sharing and adherence to antihypertensives for low and high adherers.
7046358 - The juvenile justice system and its treatment of the juvenile: an overview.
2913388 - Comparing tobacco cigarette dependence with other drug dependencies. greater or equal '...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  56     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-02-14     Completed Date:  2001-05-10     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  755-61     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, Postgraduate Insitute of Medical Education and Research, Chandigarh, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angina, Unstable / drug therapy*,  economics*
Drug Costs
Drug Prescriptions / economics
Drug Utilization / economics*,  statistics & numerical data*
Female
Fibrinolytic Agents / economics,  therapeutic use
Heparin / economics,  therapeutic use
Hospitalization / economics
Humans
India
Male
Nitroglycerin / economics,  therapeutic use
Vasodilator Agents / economics,  therapeutic use
World Health Organization
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Vasodilator Agents; 55-63-0/Nitroglycerin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of physician's education, drug information and medical-care settings on the quality of dru...
Next Document:  Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case...